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ABSTRACT
Recruitment of the mRNA capping enzyme
(CE/RNGTT) to the site of transcription is es-
sential for the formation of the 5′ mRNA cap, which
in turn ensures efficient transcription, splicing,
polyadenylation, nuclear export and translation of
mRNA in eukaryotic cells. The CE GTase is recruited
and activated by the Serine-5 phosphorylated
carboxyl-terminal domain (CTD) of RNA polymerase
II. Through the use of molecular dynamics sim-
ulations and enhanced sampling techniques, we
provide a systematic and detailed characterization
of the human CE–CTD interface, describing the
effect of the CTD phosphorylation state, length and
orientation on this interaction. Our computational
analyses identify novel CTD interaction sites on the
human CE GTase surface and quantify their relative
contributions to CTD binding. We also identify, for
the first time, allosteric connections between the CE
GTase active site and the CTD binding sites, allowing
us to propose a mechanism for allosteric activation.
Through binding and activity assays we validate the
novel CTD binding sites and show that the CDS2
site is essential for CE GTase activity stimulation.
Comparison of the novel sites with cocrystal struc-
tures of the CE–CTD complex in different eukaryotic
taxa reveals that this interface is considerably more
conserved than previous structures have indicated.
INTRODUCTION
mRNA capping is an essential process required for effi-
cient gene expression and regulation in all eukaryotic or-
ganisms (1). The mRNA cap prevents degradation by 5′-
exonucleases during transcription and acts as a platform to
recruit initiation factors required for splicing, polyadenyla-
tion, nuclear export and translation (2–8). mRNA is capped
at the 5′-end with an inverted 7-methylguanosine moiety.
This process occurs in three stages: (i) the 5′-end triphos-
phate is hydrolysed to diphosphate; (ii) GMP is covalently
linked to the diphosphate 5′ end; (iii) the guanosine base
is methylated at the N7 position (1). In animals, the first
two stages are performed by a bifunctional protein, the
capping enzyme (CE/RNGTT), which contains triphos-
phatase (TPase) and guanylyltransferase (GTase) enzymatic
domains separated by a disordered linker (9,10). The mam-
malian CE GTase functions independently of the TPase do-
main (10–12). The final step, N7 methylation of the guano-
sine base, is performed by RNMT in complex with its acti-
vating mini-protein RAM (13,14).
The process of mRNA capping is tightly coupled to tran-
scription, occurring during the elongation phase (15,16).
At this stage, the CE is recruited to the site of transcrip-
tion by the RNA polymerase II (Pol II) carboxyl-terminal
domain (CTD) (17,18). The CTD is located in RPB1, the
largest subunit of RNA Pol II, and is composed of a tan-
dem repeated heptad motif with the consensus sequence
Y1S2P3T4S5P6S7 (19,20). This domain is disordered and
can be dynamically phosphorylated at several positions to
form a highly complex pattern known as the CTD phospho-
rylation code, which is used to recruit and regulate the tran-
scription machinery, including the capping enzymes, at the
correct phase of transcription (17,18,20,21). Although each
of the residues Tyr1, Ser2, Thr4, Ser5 and Ser7 can be phos-
phorylated and have all been shown to vary in their levels
of phosphorylation during the transcription cycle, one fun-
damental transition occurs from the Ser5 to Ser2 phospho-
rylation state (pSer5 and pSer2) during transcription elon-
gation (20,22–24). The CE GTase domain is known to bind
to the CTD during the elongation phase when the CTD is
phosphorylated at the Ser5 position (12,15,16,25). This lo-
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Figure 1. Structure of the capping enzyme GTase domain and its interac-
tions with RNA Pol II CTD. (A) Structure of the human GTase domain
(PDB ID: 3S24) (10) with one RNA Pol II CTD heptad (shown as sticks)
bound in the conformation as resolved in the mouse GTase–CTD complex
by Ghosh et al. (PDB ID: 3RTX) (32). Three subdomains of the GTase
are labelled and coloured in green (NT), orange (OB) and blue (Hinge).
GTP and Mg2+ (shown as spheres) were modelled in representative binding
poses of the first enzymatic step and indicate the location of the active site.
Important secondary structural elements are labelled following assignment
in Chu et al. (10). (B) The GTase–CTD interface displaying the previously
identified CTD interaction sites on the GTase: a pSer5 charged pocket
(CDS1, composed of R330, K331 and R386) and a Tyr1 interaction site
(CDS–Y1, composed of F367, V372, C383 and E387). The pSer2 group
is solvent exposed and forms no interactions with the GTase residues. (C)
Electrostatic potential surface of the human CE GTase. Positively charged
regions (blue) have the potential to form additional pSer interaction sites.
The pSer interaction sites discussed in this work––CDS1 and a novel site
CDS2––are labelled.
calizes the CE to the site of transcription and increases the
rate of the first step of GTase catalysis. However, the impor-
tance of this activation effect on the regulation of mRNA
capping remains unclear, with recent experiments indicat-
ing that the primary role of the GTase–CTD interaction is
recruitment rather than allosteric activation (26,27). Inter-
estingly, the GTase can also bind to Ser2 phosphorylated
CTD, however, this interaction does not stimulate GTase
activity (12).
The CE GTase is highly conserved among eukaryotic
organisms and is composed of three subdomains: (i) the
nucleotidyltransferase (NT) domain, which contains essen-
tial residues involved in catalysis, (ii) the oligonucleotide-
binding (OB) domain, predicted to bind mRNA for cap ad-
dition and (iii) the hinge domain that enables large-scale
conformational changes to occur, opening and closing the
active site to facilitate substrate binding, catalysis and prod-
uct release (Figure 1A) (10,28,29). Three cocrystal struc-
tures of the eukaryotic CE GTase interacting with the Pol
II CTD fragments were previously reported: one mouse
GTase and two from yeast (Candida albicans and Schizosac-
charomyces pombe) (30–32). Although the CTD binds to the
NT domain in all of these structures, they display distinct
CTD docking sites (CDSs). This has led to the conclusion
that CTD recognition by the GTase is performed by distinct
molecular mechanisms, with different taxa independently
evolving different CTD interaction sites on the GTase sur-
face (30,32,33).
The relatively low binding affinity of the CTD to the
CE GTase (Kd = 139 M) (32), in combination with the
disordered and flexible nature of the CTD (34), the pro-
posed CTD heptad looping out mechanism (31), and the
GTase domain open-close motion (10,28,29) makes crystal-
lographic and biophysical characterization of this interac-
tion challenging. As a result, only short fragments of the
CTD bound to the GTase have been resolved, e.g. only one
CTD heptad was resolved in the mammalian GTase–CTD
structure (Figure 1B) (32). However, much longer CTD pep-
tides are required in order to elicit the stimulation of GTase
activity, suggesting that a more extensive GTase–CTD in-
teraction must occur (12). There are a number of positively
charged regions in the mammalian CE GTase that have
the potential to form additional pSer interaction sites (Fig-
ure 1C). In addition, the available GTase–CTD cocrystal
structures provide no insights into the GTase allosteric ac-
tivation mechanism, with the GTase conformations in the
cocrystal structures being almost identical to their CTD-
unbound equivalents (30–32). Nor do the current structural
studies identify the differences between the pSer5 and pSer2
CTD interactions with the GTase that could explain why
the activation effect is observed with the pSer5 CTD but
not the pSer2 CTD (12). Therefore, there are a number of
outstanding questions in the field: (i) how does the CTD
phosphorylation code affect CTD binding to the GTase?;
(ii) what additional GTase–CTD interactions are required
for GTase activation?; (iii) how is information relayed be-
tween the GTase active site and the CTD binding sites, i.e.
what is the pathway and mechanism of allosteric regulation?
Computational techniques such as molecular dynamics
(MD) simulations are well posed to answer these open ques-
tions and generate a more detailed characterization of the
GTase–CTD interaction (33). MD simulations are increas-
ingly used in the characterization of protein conformational
dynamics and protein–peptide interactions, including en-
ergetics. Recent studies highlight the application of MD
simulations to understand the conformational ensembles
of protein systems, protein allostery and protein–peptide
interactions (35–40). It must be mentioned that atomistic
MD simulations are computationally expensive, typically
limiting simulations to nanosecond-microsecond timescales
(41). Since many events in protein systems occur on longer
timescales, enhanced sampling techniques have been devel-
oped and successfully applied to overcome these limitations
and sample longer-timescale processes (42,43). Accelerated
molecular dynamics (aMD) is one such technique that in-
creases the conformational sampling of a system by reduc-
ing the depth of free-energy minima while maintaining the
characteristics of the energy surface (44–48).
Here, we carry out a large-scale computational study by
performing both conventional MD (cMD) and accelerated
MD simulations to assess the conformational dynamics of
the human CE GTase and provide a systematic and detailed
characterization of its interaction with the CTD in differ-
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ent phosphorylation states. We identify two novel CTD in-
teraction sites on the human CE GTase surface. We sub-
sequently reveal conformational changes that connect the
GTase active site to the CTD binding sites, providing the
first insights into the mechanism of GTase allosteric activa-
tion. The novel CTD binding sites are predominantly con-
served throughout animals and yeasts, indicating that the
core features of the GTase–CTD interface have undergone
considerably higher selection pressure than previously rec-
ognized. In addition, we propose that the GTase–CTD in-
teraction is bidirectional and recognize the palindromic na-
ture of the CTD.
MATERIALS AND METHODS
System preparation
The 3.0 Å resolution crystal structure of the human CE
GTase (residues 229–565) (10) was used in simulations of
the GTase systems. The systems prepared for MD simula-
tions were constructed in PyMOL (49) based upon crys-
tal structures of CE GTases available in the Protein Data-
bank (PDB): (i) the human CE apo-GTase (PDB ID: 3S24,
Chain F) (10), (ii) the mouse CE GTase in complex with
one CTD heptad (PDB ID: 3RTX, Chains B and C) (32),
(iii) the C. albicans CE GTase in complex with ∼2.5 CTD
heptads (PDB ID: 1P16, Chains B and D) (31) and (iv)
the Paramecium bursaria Chlorella virus 1 (PBCV-1) holo-
GTase domains (PDB ID: 1CKM, Chain A) (28). The
human apo CE GTase crystal structure has seven GTase
molecules in the asymmetric unit, varying in their confor-
mational states between the ‘open’ and ‘closed’ conforma-
tion of the active site cleft. All simulations were started from
the most open state (molecule F). All current crystal struc-
tures of the mammalian GTase miss portions of the 2–
D loop (residues 425–433). This was modelled with Mod-
Loop using the MODELLER loop modelling procedure
(50). All simulations were performed in the apo state, i.e.
without ligands (GTP, RNA or magnesium), in the pres-
ence or absence of the CTD. A total of 17 simulation sys-
tems were prepared: the WT and mutant systems, with dif-
ferent length, conformation, orientation and phosphoryla-
tion code of the bound CTD fragment. Supplementary Ta-
ble S1 provides a summary of all the simulations presented
in this work (17 simulation systems; 51 cMD and 33 aMD
simulations), with details of each system setup described
below.
To simulate the CE GTase–CTD complex, the mouse
GTase–CTD complex structure and human apo-GTase
structure were aligned and the 1-heptad CTD fragment was
superimposed onto the human CE GTase. To model the
4-heptad systems, the PEP-FOLD server (51) was used to
generate the starting peptide structures of three additional
heptads (21 residues). These three heptads were then fused
onto the 1-heptad CTD resolved in the mouse GTase–CTD
cocrystal structure, either onto its C- or N-terminus (Sup-
plementary Table S1). Unique starting conformations were
used for each replicate of the simulation by selecting differ-
ent PEP-FOLD-generated structures.
All simulations were prepared within the LEaP module in
the AMBER16 suite (52) using the ff14SB force field (53),
with phosphoserine modifications described by Homeyer
et al. (54). All protein and peptide chains were capped with
acetyl (ACE) and amino (NME) groups on the N- and C-ter
respectively, and Reduce was used to protonate all residues
in their standard protonation state at neutral pH (55). All
CTD phosphoserines were modelled in the −2 charge state.
Simulations of the 4-heptad, pSer5 CTD system were also
performed with the pSer in the −1 charge state and show
comparable qualitative behaviour, though with a weaker in-
teraction and reduced stability of sites (data not shown).
The protein was then placed in an octahedral box of TIP3P
water molecules extending at least 15 Å from the protein.
The system was neutralized by balancing the charge with
the appropriate number of Na+ or Cl− counter ions. Finally
a combination of steepest descent and conjugate gradient
energy minimization was performed.
Simulation setup and protocols
All standard simulations were performed using the
pmemd.cuda module of AMBER16 (52). After energy
minimization, the system was heated from 100 to 310 K over
25 ps, restraining the solute. Equilibration was performed
for 200 ps with the solute restraints gradually removed.
After 200 ps of equilibration, hydrogen mass repartitioning
was performed and the step size was increased from 2 to
4 fs for the production runs (56). Berendsen barostat and
thermostat were used to keep pressure and temperature
constant (1 atm and 310 K) during the simulations (57).
The non-bonded interaction cutoff distance was set to 10.0
Å and the SHAKE algorithm used to restrain hydrogen
bond lengths (58). To reduce neutralizing counterion
clustering around the phosphate groups of the CTD, a 20
Å distance restraint (k = 20.0 kcal/mol·Å) was imposed
between all sodium counterions and phosphorus atoms
of the CTD phosphoserines. Three replicates of each
production run were performed by randomly generating
the starting velocities.
aMD runs were performed with the AMBER16 imple-
mentation using the ‘dual-boost’ protocol as described pre-
viously (46,47,52,59,60). Briefly, this applies a potential en-
ergy boost to all atoms and an additional dihedral boost
to torsion angles. The mean potential and torsion energies
of each system was calculated from the last 50 ns of each
200 ns cMD replicate. These were then used to calculate the
aMD parameters (EP, αP, ED, αD) based upon the guide-
lines described by Pierce et al. (46). Three aMD replicates
were performed for either 200 ns or 1 s.
Data analysis
VMD and PyMOL were used to inspect and visualize the
trajectories (49,61). Analysis of the MD trajectories was
performed primarily in the CPPTRAJ module of the AM-
BER16 suite to compute interatomic distances, solvent ex-
posure, root-mean-square deviations (RMSDs) and root-
mean-square fluctuations (RMSFs) (52). Interatomic dis-
tances between CTD residues and the GTase residues were
computed using the closest CTD residue from any of its
heptads. All trajectories were analysed by using frames
saved every 40 ps. Electrostatic potentials were generated
using the Adaptive Poisson–Boltzmann Solver (APBS) im-
plemented in the PyMOL APBS tools (62). Normal mode
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analysis was performed using the ElNémo web server us-
ing the default settings (63). Multiple sequence alignments
were performed in Jalview using the Clustal Omega algo-
rithm with default settings (64,65), selecting only reviewed
protein sequences from the NT domain InterPro family
(IPR001339).
The binding free energy analysis was performed using
the Molecular Mechanics-Generalized Born Surface Area
(MMGBSA) method using the MMPBSA.py package (66)
and following the protocol described by Genheden et al.
(67). The final snapshots of the aMD simulations were
taken from the three replicates of each system. These snap-
shots were used as starting structures for 50 × 200 ps sim-
ulations. MMGBSA analysis, including per residue decom-
position, was then performed using snapshots from these
simulations with an 8 ps time step. In silico mutagenesis
was performed on the final aMD snapshots followed by
50 ns of unrestrained equilibration. The MMGBSA pro-
tocol was then performed on the mutant structures as de-
scribed above.
An additional search for potential CTD binding sites
on the CE GTase was performed with the PIPER-
FlexPepDock global protein–peptide docking server (68).
Default settings were chosen for all conditions. The server
does not accept non-standard residues, therefore, gluta-
mates were used as phosphomimetics to replace the CTD
phosphoserines.
Disorder prediction of the CE sequence was performed
using the MetadisorderMD2 server (69).
Expression and purification of recombinant proteins
The DNA sequences of the human CE GTase and each
sequence variant were synthesized and subcloned into the
PGEX6p1-C-His plasmid vector by Thermo Fisher Gen-
eArt. The PGEX6p1-C-His vector contains an N-terminal
HRV 3C cleavable tag and a C-terminal hexahistidine tag.
These plasmids were then transformed into BL21 (DE3) Es-
cherichia coli and were cultured in 200 mL of Power Broth
(Molecular Dimensions) at 37◦C until A600 was between
0.6 and 0.8. Protein expression was induced with 1 mM
IPTG overnight at 16◦C. Cells were pelleted and frozen be-
fore protein purification at −80◦C. The cells were lysed in
5 mL of lysis buffer (50 mM Tris–HCl, pH 7.5, 500 mM
NaCl, 30 mM imidazole, 1 mM TCEP, 0.2% Tween and
5 units/mL benzonase nuclease) and sonicated for 10 min
with 10 s pulses. The GTase was purified with metal affinity
chromatography, through a 1 mL HisTrap HP column (GE
Healthcare) and eluting with 350 mM imidazole. The GST
was cleaved with GST-tagged HRV 3C protease (PreScis-
sion Protease, GE Healthcare). The GST and protease was
removed with glutathione sepharose resin. Further purifica-
tion was performed with size exclusion chromatography on
a Superdex 75 10/300 GL column (GE Healthcare), resolv-
ing in a buffer of 20 mM Tris HCl (pH 7.5), 200 mM NaCl
and 1 mM TCEP. Aliquots were stored with 10% glycerol.
Purity was assessed by SDS-PAGE and Coomassie Blue
protein staining and all recombinant proteins were tested
for basal GTase activity as described below (Supplementary
Figure S8).
CTD pull down assays
GTase–CTD peptide binding assays were performed as
described by Ho et al. (12). 1 nmol of biotinylated 4-
heptad CTD peptides (PeptideSynthetics) were incubated
with 0.5 mg of streptavidin-coupled magnetic Dynabeads
M-280 (Invitrogen) in 300 L of buffer A (25 mM Tris–HCl,
pH 8, 50 mM NaCl, 1 mM TCEP, 5% glycerol and 0.03%
Triton X-100) for 45 minutes at 4◦C. Next, the beads were
magnet concentrated and washed three times with 0.5 mL
of buffer A. 4 g of the purified GTase sample was then
incubated with the beads in 50 L buffer B (Tris–HCl, pH
8, 53 mM NaCl, 1 mM TCEP, 5% glycerol and 0.03% Tri-
ton X-100) for 45 minutes at 4◦C. After incubation, the
solution was collected as the unbound fraction, the beads
were washed three times with buffer A and the bound frac-
tion was eluted with 50 L of SDS-PAGE loading buffer at
100◦C for 5 minutes. Fractions were concentrated and anal-
ysed with SDS-PAGE and Coomassie Blue staining. Bands
were quantified in ImageJ and normalized relative to the
wild-type CE GTase (residues 211–597) incubated with the
Ser5 phosphorylated CTD peptide.
Guanylyltransferase activity assays
Guanylyltransferase activity assays were performed as de-
scribed by Ghosh et al. (32). 1 M of purified human CE
GTase was incubated for 1 hour with CTD peptides of dif-
ferent concentrations (0, 2.5, 5, 10, 20, 40, 60, 80 and 100
M) in a buffer of 20 mM Tris–HCl (pH 8.0) and 50 mM
NaCl. After incubation, the guanylyltransferase activity as-
say was initiated by adding 2 L of the GTase–CTD mix-
ture into a total volume of 20 L of assay buffer. The final
activity assay buffer was composed of 0.1 M CE GTase,
20 mM Tris–HCl (pH 8.0), 50 mM NaCl, 5 mM DTT, 0.2
M GTP (10% 32P, Perkin Elmer), 5 mM MgCl2 with
varying concentrations of 4-heptad CTD peptide (0, 0.25,
0.5, 1, 2, 4, 6, 8 and 10 M). Reaction mixtures were incu-
bated at 37◦C for 10 minutes and quenched with 1× load-
ing buffer at 65◦C for 10 minutes. 15 L of each sample was
run on an SDS–PAGE gel. The gels were fixed with 30%
methanol and 5% acetic acid, stained with Coomassie Blue
and exposed to a phosphorimaging plate for 1 hour. The
plates were scanned using an Amersham Typhoon phos-
phorimager with the bands quantified in ImageJ and nor-
malized relative to the basal wild-type CE GTase activity.
RESULTS AND DISCUSSION
The human CE GTase exhibits different conformational dy-
namics from the viral enzyme
To our knowledge the human capping enzyme guanylyl-
transferase domain (CE GTase) has not been simulated be-
fore. Therefore, our first aim was to assess the conforma-
tional dynamics of the protein. To characterize the confor-
mational changes involving the GTase subdomains, the hu-
man CE GTase was simulated starting from the open state,
without the CTD bound, and running 200 ns of cMD fol-
lowed by 200 ns of aMD. In all replicates the structure en-
ters the closed conformation and remains stable for the du-
ration of the simulations (Supplementary Figure S1A). The
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NT and OB subdomains remain quasirigid, with RMSDs
<5 Å (Supplementary Figure S1B and C), similar to pre-
vious studies of GTase structures (28,29,70). As expected,
these fluctuations are higher during the aMD simulations.
An important feature of GTase domains is the large-scale
open-closed transition of the active site cleft, which is re-
quired for substrate binding, catalysis and product release
(10,28,29). A previous computational study investigated the
Paramecium bursaria Chlorella virus (PBCV-1) CE GTase
and showed that the apo state can readily adopt the closed,
open and hyperopen conformations (29). In contrast, in our
simulations the apo human CE GTase samples the open
and hyperopen states only briefly before becoming stabi-
lized in the closed state (Figure 2A, Supplementary Fig-
ures S1A and S1D). For comparison, we also ran simula-
tions of the PBCV-1 GTase, and focused our analysis on the
inter-domain distance. In contrast to the human CE GTase,
the PBCV-1 GTase readily adopts the open and hyperopen
states, fully consistent with the results of Swift et al. (29)
(Figure 2A and B). This confirms that the two enzymes in-
deed exhibit strikingly different global dynamics.
To further characterize these large-scale conformational
changes normal mode analysis (NMA) was performed on
the human and PBCV-1 GTase structures (Figure 2C and
D). The NMA results provide additional support to the
above result, showing that for both structures the lowest
frequency modes involve the domain opening and closing
motion. However, this mode differs significantly between
the two proteins. In the human CE GTase it is a rotation
of the OB and NT domains relative to each other (Figure
2C). In contrast, for the PBCV-1 CE GTase the lowest fre-
quency mode shows a straight open-close motion (Figure
2D). These differences in the global conformational dynam-
ics are likely a result of the number of salt bridges that are
able to form between the NT and OB domains (Figure2E
and F). In the human CE GTase, there is a complex network
of salt bridges which hold the domains in the closed state,
whereas in the PBCV-1 CE GTase no more than three salt
bridges can be observed at any point during the simulations.
Interestingly, a number of residues involved in salt bridge
formation between the NT and OB domains in the human
CE GTase––namely K460, D468, R528, R530, D532 and
K533––have also been shown to be important residues for
GTP and mRNA binding and mammalian CE GTase catal-
ysis (10,71,72). However, the enzyme kinetics of the CE
GTase have only been characterized in PBCV-1 and not the
human CE GTase (73). The observed dramatic differences
in the domain opening/closing dynamics between the two
proteins suggest that the kinetics of the human enzyme will
be significantly altered compared to that of the viral en-
zyme.
The CTD forms an extensive interaction with the CE GTase,
including two novel sites
The interaction between the CE GTase and the C-terminal
domain of RNA Polymerase II (CTD) is essential for GTase
activation and CE recruitment to the site of transcription
(12,15,17). It has previously been shown that interactions
with multiple heptads are required for GTase activation
(12). As a starting point for understanding the interaction
between the human CE GTase and the CTD, we initially
carried out MD simulations of the GTase in the presence
of one heptad of the CTD. These simulations were started
from the CTD conformation and phosphorylation state ob-
served in the mouse GTase–CTD cocrystal structure, which
resolved only one heptad, phosphorylated at both the Ser2
and Ser5 positions (32). Our cMD results were consistent
with the previous experimental data (Supplementary Figure
S2): pSer5 remains bound to the positively charged pocket
formed by R330, K331 and R386 (CDS1 site) in the con-
formation adopted in the crystal structure; in contrast, the
pSer2 sidechain remains solvent exposed and does not form
stable interactions with the protein. During the aMD sim-
ulations the CTD peptide samples much wider conforma-
tional space (Supplementary Figure S2). While the pSer5
interaction remains predominantly stable, the pSer2 residue
changes conformation allowing it to also occasionally inter-
act with the pSer5 pocket, CDS1. In addition, Tyr1 exhibits
a greater extent of conformational flexibility, dissociating
and rebinding to the tyrosine binding site (CDS–Y1).
Activation of the mammalian GTase strongly depends on
the length of the CTD it interacts with, with the activation
effect increasing 3-fold from two to six heptads (12). Acti-
vation is also dependent on the CTD being phosphorylated
at the Ser5 position (12,32). This indicates that the CTD
forms an extensive interaction with the GTase that requires
the binding of multiple CTD heptads. Currently there are
no crystal structures of the mammalian CE GTase in com-
plex with multiple CTD heptads. In order to systematically
characterize the extensive interaction between the longer
CTD fragments and the human CE GTase, we extended the
length of the CTD peptide to four heptads by modelling
three additional heptads onto the termini of the 1-heptad
CTD fragment, which was resolved in the mouse crystal
structure (32), in both directions. To investigate the effect
of the CTD phosphorylation code on the GTase–CTD in-
teraction, three phosphorylation states were simulated: un-
phosphorylated, Ser5 and Ser2 phosphorylated (Supple-
mentary Table S1). In each phosphorylation state, the CTD
peptide was extended in both the N- and C-ter directions in
separate simulation systems, yielding six different systems,
to identify interaction sites that might occur at different
sides of the known CTD interaction sites (CDS1 and CDS–
Y1) (Supplementary Figure S3). Three replicates were per-
formed using different CTD starting conformations to en-
sure that the interactions formed were reproducible and not
biased by the initial CTD conformation (Supplementary
Figure S3).
Analysis of the 4-heptad pSer5 CTD simulations (Sys-
tems 6 and 7) provided valuable insights into the GTase–
CTD interaction (Figure 3). The previously reported CDS1
site remains occupied in all replicates (Figure 3B). The
CDS–Y1 interaction remains stable for the duration of the
cMD simulations but becomes destabilized, dissociating
and rebinding, during the aMD simulations (Figure 3D). In
addition to CDS1 and CDS–Y1, our simulations identify
two novel CDS sites––named CDS2 and CDS–Y2––that
were not observed in the mouse crystal structure of the com-
plex (Figure 3 and Movie S1) (32).
The first novel CDS site, CDS2, is a pSer5 interaction
site composed of sidechains R358, K403 and R411 that
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Figure 2. Conformational dynamics of the apo human CE GTase domain in comparison with the apo PBCV-1 CE GTase. Top panels (A, C, E) refer to the
human GTase (10), and lower panels (B, D, F) refer to the PBCV-1 GTase (28). (A, B) Conformational distributions obtained from cMD simulations. The
inter-domain distance was taken as the separation between the centres of mass of the NT and OB domains. Histograms were constructed using the data
from all cMD replicates. (C, D) The results of the normal mode analysis, visualizing conformational changes in the protein. The lowest frequency mode
relating to the open-close motion is depicted as a porcupine plot, with the arrows representing the direction and amplitude of motion for each residue. (E,
F) Salt bridges forming between the OB and NT domains of the GTase upon domain closure.
form multiple electrostatic interactions with the phosphate
group of pSer5 of the CTD (Figure 3A, C and Movie S2).
The CDS2 site is located within a positively charged patch
on 7, 8 and loop C–8. This interaction is very sta-
ble, remaining occupied once pSer5 binds to the site, and
is observed in all replicates of System 6 (Figure 3C). In the
no-CTD state, the basic residues that constitute the CDS2
site are predominantly solvent exposed and are involved in
transient interactions with surrounding negatively charged
groups, including D349, D402, E406 and E432. No large-
scale conformational changes occur upon pSer5 binding to
CDS2, ruling out an induced fit mechanism.
The second novel CDS site identified by simulations is
a tyrosine pocket, CDS–Y2. This accommodates the Tyr1
residue of the CTD, through hydrophobic interactions of
the tyrosine ring with L381 at the centre of the pocket and
F377, P414 and F416 in the vicinity (Figure 3A, E and Sup-
plementary Movie S3). This pocket is partially occupied by
Tyr1 in all replicates, however, it represents a transient in-
teraction and was easily destabilized during the aMD sim-
ulations (Figure 3E). The CDS–Y2 residues are located on
helix C and loop 8–D. They are semi-buried within the
NT-Hinge interface, reducing their solvent exposure, and
interact with a number of adjacent hydrophobic residues
that form part of a hydrophobic region that includes W293,
Y362, I384, F416 and T445. Although there is no large-
scale conformational change associated with Tyr1 binding
to this site, many of these residues interact directly with the
residues involved in GTP binding. Therefore, Tyr1 binding
to this site might have an effect on GTP binding or coordi-
nation.
Due to their electrostatic nature, the pSer5-CDS interac-
tions (CDS1 and CDS2 sites) remain stable once formed
(Figure 3B and C). During aMD simulations, some indi-
vidual CDS1 interactions are occasionally broken, however
pSer5 remains bound to this region. Upon CDS2 binding,
this interaction remains stable with only minor fluctuations.
In contrast, the Tyr1 interactions are considerably less sta-
ble (Figure 3D and E). CDS–Y1 remains occupied by Tyr1
for the duration of the cMD, however all replicates show
Tyr1 dissociation and rebinding during the aMD stage. This
is also observed with the CDS–Y2 pocket, which again rep-
resents a transient interaction, despite being occasionally
observed in all replicates.
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Figure 3. CTD interaction sites observed during the simulations of the GTase with the 4-heptad pSer5 CTD extended in the N-ter direction (System 6).
(A) Locations on the GTase (left) and residues involved in the four CTD interaction sites (panels on the right) reproducibly observed in these simulations.
The snapshot shows a representative CTD binding conformation and the positions of the N- and C-terminal heptads are indicated. (B–E) Time-evolution
of the minimum distances showing the occupation of each CDS by the respective CTD group (pSer5 or Tyr1) over the duration of the cMD and aMD
simulations. Distances obtained in three replicates are shown in orange (replicate 1), blue (replicate 2) and green (replicate 3). The occupation of each site
was described by taking representative sidechain minimum distances as follows: (B) CDS1, R330 sidechain nitrogens to the pSer5 phosphate oxygens, (C)
CDS2, R411 sidechain nitrogens to the pSer5 phosphate oxygens, (D) CDS–Y1, V372 C atoms to the Tyr1 ring and (E) CDS–Y2, L381 sidechain to the
Tyr1 ring. Distances from the CTD groups to other residues in the respective pockets (e.g. R386 and K331 in CDS1) show comparable behaviour.
A further inspection of the previous cocrystal structure
of the mouse GTase–CTD complex provides a rationale to
explain why the newly identified CTD interaction sites, i.e.
CDS2 and CDS–Y2, were not observed in that structure
(32). The asymmetric unit of the structure forms a homod-
imer between two GTase domains, which was considered an
artefact of crystallization (Supplementary Figure S4). This
homodimer interface forms extensive contacts on the NT
domain and the hinge, occluding the CDS2 and CDS–Y2
sites, close to the bound CTD heptad. As a result, the dimer
interface obstructs the CDS2 and CDS–Y2 sites, preventing
CTD binding to this region. We expect that future structural
studies of the mammalian GTase will confirm CTD binding
to these novel sites.
An important feature of our simulations is that although
the novel CDS2 and CDS–Y2 interactions are observed re-
producibly in all replicates (Figure 3C and E), these inter-
actions can occur on different heptads between the repli-
cates (Supplementary Figure S5). The CDS1 and CDS2
sites can be occupied either by adjacent CTD heptads or
heptads can be looped out, with non-neighbouring hep-
tads occupying CDS1 and CDS2. This provides evidence
of the ‘looping out’ mechanism suggested in previous stud-
ies, which showed that the CE must interact with multiple
heptads but that these do not need to be adjacent in se-
quence (31). The simulations also show that the order of
the CDS interactions can vary. This can be seen, for exam-
ple, in replicate 2 where heptad 4 dissociates from CDS–Y1
and is replaced by heptad 3, switching the order of CDS1
and CDS–Y1 (Supplementary Figure S5). Both conforma-
tions are stable and this change does not destabilize other
CDS interactions. Therefore, CDS sites can be occupied in
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different heptad orders as well as heptads being looped out.
During GTase recruitment the CTD is not uniformly Ser5
phosphorylated (25), and so the looping out mechanism we
observe is consistent with the hypothesis that unphospho-
rylated CTD heptads are looped out during GTase recruit-
ment to enable the CTD to bind to all the CDS sites (31).
Phosphoserine interaction sites are critical for CTD binding
to the GTase
Our simulations revealed two additional CTD interaction
sites on the human CE GTase surface. However, the con-
tribution and importance of each CDS site to the CTD
binding to the GTase remained unclear. MMGBSA is a
computational technique that can be used to predict the
binding free energies between binding partners, including
protein-peptide complexes (see Materials and Methods for
details) (66,67,74,75). In order to obtain a detailed quan-
titative characterization of the GTase–CTD interaction,
MMGBSA calculations were performed to assess the bind-
ing affinities and the contributions of individual residues.
The MMGBSA analysis identified the main GTase residues
that contribute to CTD binding (Figure 4). Results for the
4-heptad pSer5 simulations extended in the N-ter direction
(System 6) are shown in Figure 4A. As expected, the core
residues comprising the pSer5 interaction sites––residues
R330 and R386 of CDS1 and R358, K403 and R411 of
CDS2––make the largest contributions to the GTase–CTD
interaction. Notably, arginines make the most significant
contribution to the binding free energy, whereas the flexi-
bility of the CDS lysine sidechains and their position on the
loops in the CE GTase make them more likely to dissociate
from CTD interactions. This can be seen in CDS1 where
R330 and R386 make the largest contributions to the CTD
binding affinity, whereas K331 makes a relatively small con-
tribution. Likewise, in CDS2, R358 and R411 make the
largest contributions to the binding affinity, whereas K403
makes a smaller contribution because of its location on
a loop. R392 is included as a CDS2 residue, however it
forms a strong interaction with pSer5 only in one replicate,
whereas in the other two replicates it forms a stable salt
bridge with E406 in the NT domain; this explains a large
standard deviation for this residue. No other residues on
the CE GTase make significant contributions to the bind-
ing affinity, confirming the central role of CDS1 and CDS2
sites in the GTase–CTD interaction.
In contrast to the pSer5 sites, the Tyr1 sites make a
minor contribution to the binding affinity, with none of
the CDS–Y1 or CDS–Y2 residues contributing more than
−5 kcal/mol (Figure 4A). This is consistent with their tran-
sient nature seen in the aMD distance analysis (Figure 3D
and E). Despite this, mutagenesis of Tyr1 to alanine has
been previously shown to significantly decrease GTase bind-
ing and activation (76). This suggests that Tyr1 has an im-
portant but more subtle role in GTase recruitment and ac-
tivation.
As pSer5 interactions were found to dominate the
GTase–CTD interaction, in silico mutagenesis was per-
formed to further assess the importance of each site and to
guide biochemical experiments (Figure 4B). We constructed
mutant systems in which CDS1 (R330, K331 and R386)
Figure 4. Quantitative analysis of the CTD binding affinity to the GTase.
MMGBSA calculations (see details in the Methods) were performed on
three replicates of the simulations containing the 4-heptad pSer5 CTD ex-
tended in the N-ter direction (System 6). (A) Per-residue decomposition
analysis of the binding free energy. The key GTase residues that contribute
to CTD binding are labelled and coloured according to the CDS site they
belong to (see the plot legend box). The residues making significant con-
tributions (below –2.1 kcal/mol) are all confined to the region between
residues 320 and 440. (B) Comparison of the binding free energy between
the wild-type GTase and the three mutants, where the positively charged
residues of CDS1, CDS2 and both sites were mutated to alanine. The data
is min-max normalized relative to the lowest value over all the conditions
and the average for the WT + pSer5 condition. The result for the wild-type
GTase with unphosphorylated CTD is also shown for comparison. Error
bars denote one standard deviation. ANOVA followed by post-hoc Tukey
tests were performed to calculate statistical significance between the mu-
tants and the wild-type GTase + pSer5 CTD condition. * indicates that the
differences are significant at P < 0.05, ** indicates that the differences are
significant at P < 0.01, *** indicates that the differences are significant at
P < 0.001, and NS indicates that the differences are not significant.
and CDS2 (R358, K403 and R411) residues were mutated
to alanine in the final frames of the aMD simulations of
System 6––yielding Systems 13, 14 and 15 (Supplementary
Table S1). Each system was re-equilibrated for 50 ns and
then MMGBSA analysis was performed (Figure 4B). An
additional system containing the dephosphorylated CTD
(System 12) was simulated to provide an important refer-
ence. It must be noted that although MMGBSA results
are extremely useful to compare relative binding free en-
ergy values for different systems, the absolute binding free
energy values calculated must be taken with caution (67).
The results show that the two pSer5 CDS sites (CDS1 and
CDS2) make major contributions to the binding affinity
of the CTD. When either pocket is mutated (CDS1 or
CDS2) the binding free energy is significantly reduced.
When residues in both CDS1 and CDS2 pockets are mu-
tated to alanine, the binding free energy is reduced further
and is approximately equal to that of the unphosphorylated
CTD. These results suggest that, although the Tyr1 interac-
tions may have have an auxiliary role in GTase recruitment
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and activation, pSer5 CDS interactions form the basis of
GTase binding to the CTD.
pSer2 CTD can bind to CDS1 and CDS2 adopting different
conformations from pSer5 CTD
In order to characterize the differences in the GTase–CTD
interaction as the CTD code is changed, we simulated the
pSer2 CTD (Systems 8 and 9) and compared its conforma-
tional dynamics and interactions to that of the pSer5 CTD
(Systems 6 and 7). pSer2 is known to bind to the GTase
with comparable affinity to pSer5 but does not illicit the
GTase activation (12). Previous literature suggests that the
Ser2 phosphorylated CTD displays non-competitive bind-
ing with Ser5 phosphorylated CTD, therefore, the two states
are expected to bind to different locations on the CE GTase
surface (12). Our MD results suggest that the pSer2 CTD
also readily binds to the same sites, CDS1 and CDS2 (Fig-
ure 5 and Supplementary Figure S6). During the simula-
tions, the CDS1 pocket is quickly occupied by pSer2 due
to its close starting proximity (Figure 5B and Supplemen-
tary Figure S6A). In addition, in one of the three replicates
extended in the N-ter direction and in two of the three repli-
cates extended in the C-ter direction the pSer2 sidechain oc-
cupies the CDS2 pocket (Figure 5A, C and Supplementary
Figure S6B). Once pSer2 is bound, the respective sites re-
main occupied for the duration of the simulations. These
dynamics are similar to the pSer5 CTD. This indicates that
the CDS1 and CDS2 pockets are not specific to pSer5, and
that both pSer2 and pSer5 groups can bind to them. Im-
portantly, the conformation the pSer2 CTD adopts when
binding to the CDS2 site is different from that of the pSer5
CTD (Figure 5A). As the pSer2 residue is adjacent to Tyr1,
it reduces the Tyr1 interactions with the hydrophobic CDS–
Y1 and CDS–Y2 pockets (Figure 5D and E, Supplementary
Figures S6C and S6D). Tyr1 interactions have been impli-
cated in CE recruitment and activation by the CTD (76).
Therefore, this difference in binding mode may explain why
pSer2 CTD can bind to the human CE GTase but does not
stimulate GTase activity (12).
Disordered flanking domains contain positively charged re-
gions suitable for phosphorylated CTD binding
Our simulations provide a detailed understanding of the
CTD interactions with the GTase within a distance of
around three heptads from the site reported in the mouse
GTase–CTD crystal structure (32). However, they do not
account for interactions that could occur in more distant
regions of the human CE, such as the OB domain or within
the disordered regions at the N- and C-terminal flanks of
the GTase, which were not resolved in any of the crystal
structures (10,32). A previous crystal structure of the S.
pombe CE GTase (Pce1) displayed a Spt5 CTD docking site
in the OB-fold domain (30). Given that the full-length CTD
is 52 heptads in humans, it is not excluded that some frag-
ments of the CTD also interact with other regions of the
human CE, even when bound to the CDS1 and CDS2 sites
(19).
The task of exploring potential binding sites of a full-
length CTD on the CE GTase is unfeasible for atomistic
MD. Therefore, to explore potential binding sites in alterna-
tive regions of the GTase, global peptide docking was per-
formed using the PIPER-FlexPepDock server. Although
global protein:peptide docking is challenging and often in-
accurate, these techniques can give an indication of the re-
gions a peptide can bind to and the possible conformations
it can adopt. In particular, the results for the 2-heptad CTD
docking to the GTase show that the pSer5 CTD peptides
are localized in the NT domain in the region covering CDS1
and CDS2 (Supplementary Figure S7B). On the other hand,
the docking results for the pSer2 CTD offer a less clear pic-
ture although they still show models docked to CDS2 (Sup-
plementary Figure S7C). These observations provide addi-
tional support to our MD findings.
So far, we have focussed on the CTD binding to the CE
GTase domain. However, CTD binding to other regions of
the CE has not been fully explored. Biochemical assays have
previously shown that the phosphorylated CTD does not
interact with the TPase domain of the human CE, but the
contribution of the two disordered regions that flank the
GTase domain has not been examined previously (12). Un-
fortunately, due to the length and the disordered nature of
these regions, they could not be accurately modelled or sim-
ulated by MD simulations. Inspection of the human CE se-
quence reveals that both the disordered TPase–GTase linker
and the disordered region at the C-terminus of the GTase
contain large numbers of positively charged residues that
are found in several clusters, which could form positively
charged sites similar to CDS1 and CDS2 (Supplementary
Figure S7D). Therefore, we expect that the phosphorylated
CTD can interact with these regions in addition to the sites
in the GTase domain, enhancing the CE recruitment to the
CTD. The C-terminal flanking region has previously been
shown to be essential for the recruitment of the CE to Nck1
to enable cytoplasmic capping, further suggesting that this
region plays an important role in recruitment of the CE to
both the site of cotranscriptional and cytoplasmic capping
(77).
Biochemical assays validate the role of the phosphoserine in-
teraction sites for GTase recruitment
Our computational analyses provide a detailed picture of
the core GTase–CTD interaction offering a number of
findings that can be tested biochemically. In particular, our
results predict that: (i) pSer interactions with the CE GTase
form the basis of the binding affinity, with CDS1 and
CDS2 sites making major contributions to CTD binding
affinity, (ii) mutating out both CDS1 and CDS2 reduces
CTD binding affinity to a level comparable to the unphos-
phorylated CTD, (iii) CDS1 and CDS2 are non-specific
and can also bind the Ser2 phosphorylated CTD and (iv)
the disordered regions flanking the GTase domain contain
positively charged residues that are likely to contribute to
CTD binding. In order to validate these predictions, we
expressed and purified the recombinant human GTase pro-
teins and tested the affinity of the 4-heptad CTD peptides
(Supplementary Figure S8). A total of eight recombi-
nant proteins were prepared: the core human CE GTase
(229–569) wild-type, CDS1 (R330A/K331A/R386A),
CDS2 (R358A/K403A/R411A) and CDS1+2
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Figure 5. CTD interaction sites observed during the simulations of the GTase with the 4-heptad pSer2 CTD extended in the N-ter direction. (A) The final
snapshot of replicate 3 showing the CTD bound to both CDS1 and CDS2 interaction sites on the GTase. (B-E) Time-evolution of the minimum distances
showing the occupation of each CDS by the respective pSer2 CTD group over the duration of the cMD and aMD simulations. Distances obtained in three
replicates are shown in orange (replicate 1), blue (replicate 2) and green (replicate 3). The occupation of each site was described by taking representative
sidechain minimum distances as follows: (B) CDS1, R330 sidechain nitrogens to the pSer2 phosphate oxygens, (C) CDS2, R411 sidechain nitrogens to the
pSer2 phosphate oxygens, (D) CDS–Y1, V372 C atoms to the Tyr1 ring, (E) CDS–Y2, L381 sidechain to the Tyr1 ring.
(R330A/K331A/R386A/R358A/K403A/R411A). In
addition, WT and mutant proteins were expressed and
purified containing both disordered domains that flank
the GTase (211–597). All protein constructs had the same
behaviour during purification and showed the same basal
activity (Supplementary Figure S8C), indicating that they
are all properly folded.
First, we performed pull-down assays on all recombinant
proteins, using 4 heptad CTD peptides that were either un-
phosphorylated, Ser5 or Ser2 phosphorylated on all hep-
tads (Figure 6A–E). The WT GTase (211–597) binds to the
four heptad pSer5 CTD with an affinity comparable with
previous literature (Figure 6A) (12). We then compared the
core human GTase (229–569) and the GTase with the ad-
ditional disordered flanking domains (211–597) (Figure 6A
and B). In agreement with our prediction that these disor-
dered regions might be important for GTase recruitment,
the protein containing the flanking regions exhibits a sig-
nificantly increased CTD binding. These interactions are
not pSer5 or pSer2 specific, enhancing binding for both the
pSer5 and pSer2 CTD peptides. As both the CTD and these
flanking regions are disordered, these additional interac-
tions possibly represent the formation of a ‘fuzzy’ complex
where the CTD interacts at well-ordered sites on the GTase
surface (CDS sites) in addition to forming interactions with
the disordered flanking regions (78,79). In this case, the role
of the flanking interactions is to increase GTase–CTD bind-
ing required for CE recruitment and GTase activation.
We then sought to validate the pSer5 CTD interactions
observed on the GTase domain. Comparison of the binding
affinity of the CDS mutations shows results consistent with
our computational predictions, with the CDS1 and CDS2
sites both contributing significantly to pSer5 CTD binding
(Figure 6C and D, Supplementary Figure S9). When both of
these interaction sites are removed, GTase binding to pSer5
CTD is at a comparable level with the WT GTase binding
to the unphosphorylated CTD. This indicates that there are
no other pSer5 interaction sites on the GTase.
In further agreement with our computational results,
pSer2 CTD peptide binding also significantly decreases
when CDS1 or CDS2 residues are mutated, with the same
trend observed for the pSer5 CTD peptide (Figure 6C
and E). This result contrasts with previous literature that
showed that the pSer2 CTD binds to the human CE GTase
non-competitively with the pSer5 CTD (12). Our results
also show that pSer2 CTD has a lower binding affinity than
pSer5 (Figure 6A and B), in contrast with previous experi-
mental data that showed the pSer2 and pSer5 CTD peptides
binding to the CE GTase with comparable affinity (12).
These results are reproducibly observed in the core GTase
assays (229–569), however, without the disordered flanking
regions the low binding affinity makes it difficult to quantify
and distinguish the mutants (Supplementary Figure S9).
The novel phosphoserine pocket, CDS2, is essential for GTase
activation
Upon binding to the CE GTase, the Ser5 phosphorylated
CTD has been shown to stimulate the first step of GTase
catalysis (12). All crystal structures of the CE GTase–CTD
interaction show that the CTD binds outside of the active
site, on the NT domain, therefore this must involve an al-
losteric mechanism of activation. The nature of such an al-
losteric activation, its mechanism and importance in the
regulation of mRNA capping remain unclear (26,27). To
assess whether the novel CDS2 site is involved in the CE
GTase activation by the CTD, we performed GTase activ-
ity assays on the CDS mutant recombinant GTase proteins
(Figure 6F and G and Supplementary Figure S10). The ac-
tivity assay quantifies the first stage of GTase activity by
measuring the level of 32P-labelled guanosine monophos-
phate covalently bound to the GTase active site. Incuba-
tion of the WT GTase (211–597) with the 4 heptad pSer5
CTD increases the GTase activity by 2.2-fold, consistent
with previous literature (12). Removal of the CDS1 site re-
duces the GTase activation effect, however it still elicits ac-
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Figure 6. Biochemical assays characterizing GTase binding to the CTD and GTase activity stimulation. (A–E) Recombinant human CE GTase was in-
cubated with biotinylated peptides of four CTD heptads––in either their unphosphorylated, Ser5- or Ser2-phosphorylated states––bound to streptavidin-
coupled Dynabeads. The level of GTase binding to the CTD peptides was assessed by SDS-PAGE stained with Coomassie Blue. (A, B) Comparison of the
WT GTase constructs with (variant 211–597) and without (variant 229–569) the disordered flanks and with the 4-heptad CTD peptides (unphos, pSer2 or
pSer5). (C–E) Comparison of the CTD binding affinity to the GTase (211-597) mutants for the unphosphorylated, pSer5 and pSer2 CTD peptides. (F, G)
Guanylyltransferase activity assay of the GTase (211-597) mutants with increasing CTD concentration. Band quantification of the assays––shown in (B),
(D), (E) and (G)––was performed in triplicate and the mean was plotted, normalizing to the WT + pSer5 CTD condition. Error bars denote one standard
deviation. ANOVA followed by post-hoc Tukey tests were performed to calculate statistical significance compared to the wild-type GTase (211-597) +
pSer5 CTD condition. *** indicates that the differences are significant at P < 0.001.
tivation to 1.4-fold the basal level. In contrast, mutagenesis
of the CDS2 site completely inhibits GTase activity stimula-
tion, suggesting that it has an essential role in the allosteric
activation of the GTase. Mutagenesis of both the CDS1 and
CDS2 sites replicates the inhibition observed in the CDS2
mutant. Nearly identical results are observed with the core
GTase (229–569) (Supplementary Figure S10).
K294A GTase simulations reveal important components of
the allosteric pathway between the active site and the CTD
binding sites
Having confirmed the essential role of the CDS sites in
GTase allosteric regulation, we next aimed to identify the
underlying molecular details of this process. To this end,
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we compared the conformational dynamics of the GTase in
its pSer5 CTD-bound and no-CTD states (Supplementary
Figures S11 and S12; Systems 1 and 16). Comparison of
the aMD simulations of these two systems shows no global
changes in the GTase secondary structure (Supplementary
Figures S11A and S11B), in agreement with previous crystal
structures (31,32). In addition, the aMD simulations show
no large-scale changes in the dynamics of the GTase (Sup-
plementary Figure S12). This indicates that the complete
allosteric activation effect occurs on a timescale not acces-
sible during our simulations (i.e. longer than a few s). To
overcome this limitation, we have employed the fact that
allosteric communication is intrinsically bidirectional, and
therefore, perturbations at the other end of the allosteric
pathway, in the orthosteric site (i.e. the GTase active site)
can modulate the effector binding sites (i.e. the CDS sites)
through reversed allosteric communication (80–82). Such
perturbation is offered by the K294A mutant of the essen-
tial Lysine 294 residue at the center of the GTase active
site, which was previously reported to reduce CTD binding
(32). We hypothesized that by simulating this mutant, we
might observe the reverse modulation of the allosteric path-
way, allowing us to identify the essential residues involved
in the communication between the CTD binding sites and
the GTase active site. Therefore, we performed simulations
of the K294A mutant (System 17) using the same protocol
to assess whether this approach can reveal conformational
changes that would reduce CTD binding (Figure 7).
In the K294A system, significant conformational changes
do occur on the timescale of our simulations, relaying the
structural changes in the GTase active site to the pSer5 CTD
binding sites (Figure 7B). In particular, the change in elec-
trostatics of the K294A GTase active site results in a lo-
cal uncompensated negative charge, causing E436 to move
away from the site of magnesium binding. This leads to
the formation of salt bridges between E436 with R358 and
R411, essential residues in the CDS2 site (Figure 7C and
D and Supplementary Figure S13). These salt bridges are
highly occupied for the duration of the aMD simulations
and the involvement of R358 and R411 in the salt bridges is
expected to compete with the pSer5 CTD interactions, thus
reducing CTD binding affinity. Moreover, large-scale con-
formational changes, affecting the secondary structure ele-
ments of CDS2 and CDS1 were also observed. The primary
salt bridge is between E436 and R358. A salt bridge between
E436 and R411 can also form, and in one replicate this is as-
sociated with a large-scale conformational change that oc-
curs in helix C and loop 5–6 (Figure 7B and Supple-
mentary Figure S13). This region contains the residues that
comprise CDS1, and the conformational change displaces
these residues, thus disrupting CDS1 (Figure 7B and E).
The involvement of the positive CDS2 residues in the inter-
actions with E436 and large-scale conformational changes
in the CDS1 and CDS2 sites provide an explanation for the
reduction in CTD binding in the K294A GTase mutant. To
our knowledge, these results provide the first molecular de-
tails of the allosteric pathway that connects the GTase active
site to the CTD binding sites.
We hypothesize that in the WT the same allosteric path-
way is adopted in the ‘forward’ direction for activity stimu-
lation by the CTD. However, the timescale for relaying the
effect of CTD binding on the active site is likely to be consid-
erably longer than our current simulations (80). Partial sup-
port for this hypothesis is provided by a careful inspection
of the identified allosteric pathway in the WT GTase sim-
ulations with and without the CTD (Figure 7C and D). In
the WT CTD-unbound system (System 1), R358 and R411
exhibit higher flexibility and can adopt conformations that
support the formation of transient interactions with E436
(Figure 7C and D). These interactions cause E436 to move
away from the active site into a position that is reminis-
cent of the inactive K294A mutant. In contrast, in all pSer5
CTD-bound systems, pSer5 binding to CDS2 ensures the
involvement of R358 and R411 in the interactions with the
phosphate group (see Figure 3), which completely prevent
the formation of salt bridges with E436 (Figure 7C and D;
System 16). As E436 is adjacent to the site of magnesium
binding and the GTP/RNA binding cleft, it contributes to
the electrostatic environment of the active site. We suggest
that the CTD stimulates GTase activity by causing a popu-
lation shift of E436 conformations towards states that sup-
port magnesium and substrate binding. Additional support
to this proposal is provided by sequence conservation anal-
ysis (see the last paragraph of the next section).
The GTase–CTD interaction sites are predominantly con-
served between animals and yeasts
After identification of novel CTD interaction sites in the
simulations, we checked these in the available crystal struc-
tures of the GTase–CTD complex in other eukaryotic
species (S. pombe and C. albicans) (30,31). Previous re-
search has concluded that different taxa have evolved dis-
tinct CDS binding sites on the GTase surface to recruit the
CE to the site of transcription (30,32): although all cur-
rent GTase–CTD cocrystal structures show that the CTD
interacts with the NT domain of the CE GTase, their con-
formations and interaction sites differ significantly (30–32).
Despite this, S. pombe and C. albicans GTase–CTD cocrys-
tal structures share a number of conserved features, includ-
ing a CDS site (CDS1) composed of residues on helix C
and loop 7–C and a Tyr1 interaction site in the same lo-
cation between helix C and strand 8. Apart from these
similarities, they contain additional pSer5 interaction sites
that are not conserved between the two species or seen in
the mouse GTase–CTD cocrystal structure. When compar-
ing these yeast GTase–CTD interactions with the mouse
GTase–CTD cocrystal structure there are no conserved in-
teractions between them, although the CTD sites are always
in nearby regions of the NT subdomain (32).
Surprisingly, when comparing the novel CDS sites ob-
served in our simulations of the human CE GTase with
that in the C. albicans cocrystal structure, we find a num-
ber of similarities. Both the novel CDS2 and CDS–Y2 sites
are also observed at the same positions in the C. albicans
cocrystal structure (Figures 3A and 8A). In addition, CDS2
residues have been shown to be essential for CTD binding to
the S. cerevisiae CE GTase (83). Sequence analysis compar-
ing animal and yeast species shows that the core residues of
both CDS2 and CDS–Y2 are functionally conserved across
animals and yeasts (Figure 8B). For the CDS2 site this func-
tional conservation is not immediately apparent because, al-
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Figure 7. Comparative analysis of the WT and K294A GTase systems reveals the conformational changes that connect the GTase active site to the CTD
binding sites CDS1 and CDS2. (A, B) Representative snapshots of the predominant WT conformation (A; System 1) and K294A conformation after the
disruption of CDS1 (B; System 17). The location of the magnesium binding site is highlighted in magenta, and that of CDS1 and CDS2––by dashed red
circles (in A). The conformational changes of E436 and R411 in the K294A simulation are indicated by the red arrows and the forming salt bridge by the
dotted lines (in B). The protein regions showing significant conformational change in the K294A simulation are shown as opaque cartoon, while the rest
of the protein––as transparent. (C) Time-evolution of the minimum distances between the E436 and CDS2 residue sidechains during aMD simulations
of WT without CTD (System 1), WT + CTD (System 16) and K294A (System 17). For each system aMD replicate 1 is shown as a representative. (D)
Histogram of the minimum distances between E436 and CDS2 residue sidechains for the systems shown in (C). Data from all three aMD replicates was
used to build the histograms. (E) Backbone RMSDs of the CDS1 residues for the systems shown in C.
though R358 is highly conserved throughout animals and
yeasts, K403 and R411 are not conserved in yeasts. How-
ever, in yeasts both are substituted with nearby positively
charged residues that are highly conserved: K403 is substi-
tuted with a positively charged residue on helix C (K178 in
C. albicans) and R411 is substituted for a lysine two residues
away on the same side of strand 8 (K193 in C. albicans).
These residues are not conserved in S. pombe and the CDS2
site is not observed in its GTase–CTD cocrystal struc-
ture (30), suggesting divergent evolution in this branch of
yeasts.
The CDS–Y2 pocket identified in our simulations is
also conserved throughout animals and yeasts. The cen-
tral leucine residue (L381) is highly conserved between the
two. The additional hydrophobic residues that comprise the
pocket are highly conserved in animals and yeasts but the
specific residues in this pocket vary between the two taxa. In
animals, this pocket is composed of F377, P414 and F415,
in contrast to F63, F196 and M199 in yeasts.
The CDS1 pocket, although its precise location in loop
5–6 and helix C is not conserved between animals and
yeasts, is in the same region of the GTase across animals
and yeasts. The residues in the CDS1 pocket are highly con-
served in animals, however, the CDS1 residues are poorly
conserved throughout yeasts. Despite this, most species of
yeast contain positively charged residues in either loop 5-
6, where the mammalian CDS1 residues are located, or
on loop 7–C and helix C, the same location as in C.
albicans and S. pombe. Interestingly, R386 is highly con-
served as a positively charged residue throughout both an-
imals and yeasts. As this residue is only around 7 Å from
the CTD pSer5 sidechain in the S. pombe cocrystal struc-
ture, it is likely that this residue also contributes to CTD
binding in yeasts. This lack of conservation of the CDS1 site
is unsurprising because the majority of the CDS1 residues
are located on flexible loops where the exact position of
the positively charged residues is unlikely to affect efficient
GTase recruitment by the CTD. The CDS–Y1 hydropho-
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Figure 8. Conservation analysis of the CTD interaction sites on the GTase, comparison to the C. albicans GTase–CTD cocrystal structure, and the palin-
dromic nature of the CTD. (A) CTD interaction sites observed in the C. albicans GTase–CTD cocrystal structure (PDB ID: 1P16) (31). The positions
of the N- and C-ter heptads of the CTD are indicated. The residue numbers are from the C. albicans GTase. (B) Multiple sequence alignment of animal
and yeast CE GTase sequences in the CDS and allosteric pathway regions. Numbers above indicate the human CE residue numbers and below are the C.
albicans residue numbers. The CDS sites are indicated by coloured circles above/below the residue numbers. (C) MMGBSA analysis comparing the CTD
binding affinity to the human GTase between the ‘mammalian’ orientation (as in Figure 4; System 6) and the ‘yeast’ orientation (from the C. albicans
crystal structure extended to four heptads; System 11; see details in the Materials and Methods). (D) One CTD heptad displayed in the conventional way
(above) and then shifted and centred at Tyr1 (below) to illustrate the palindromic nature of the repeating sequence.
bic pocket, in contrast to the CDS–Y2 pocket, is highly
conserved in animals, however, does not appear to be con-
served in yeasts and it is not observed in either of the
yeast GTase–CTD cocrystal structures (30,31). Therefore,
although many of the central features of the GTase–CTD
interaction are conserved in both animals and yeasts, there
are some features that distinguish them.
In addition to the CDS sites, the essential components
(E436 and R411) of the proposed allosteric pathway are
highly conserved in animals but not in yeasts (Figure 8B):
E436 is absent in yeasts, while R411 is substituted by a lysine
at the -2 position in the sequence (K193 in C. albicans). This
lysine is further from the active site than R411, in a location
that would be incompatible with the salt bridge formation
required for the allosteric mechanism described in the previ-
ous section. As such, this lack of conservation between the
two taxa for these components could explain why allosteric
activation of the CE GTase by the CTD has been observed
in animals but not in any species of yeast (31).
The palindromic nature of the CTD code allows bidirectional
binding of the CTD
One striking difference between the conformations seen in
our simulations and those observed in the C. albicans CE
GTase–CTD cocrystal structure is that the CTD peptide
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is oriented in opposite directions (Figures 3A and 8A). In
our simulations CDS1 is occupied by a pSer5 of the C-
terminal heptad of the CTD and CDS2 by a pSer5 of an
N-terminal heptad. In contrast, the C. albicans cocrystal
structure shows CDS1 occupied by the N-terminal heptad
and CDS2 by the C-terminal heptad. This raised the ques-
tion of whether this is a characteristic feature that is dis-
tinct between mammals and yeasts or if the CTD can bind
in both directions.
To assess the stability and affinity of CTD binding to the
human CE GTase in the alternative orientation, the C. albi-
cans CTD conformation was superimposed onto the human
CE GTase, extended to four heptads and simulations were
performed as described above (Systems 10 and 11; Sup-
plementary Figure S14). The CTD conformation remains
stable for the duration of the simulations, with the same
characteristics as observed in our previous simulations: the
pSer5 pockets (CDS1 and CDS2) form strong interactions
and the CDS–Y2 site is more transient (Supplementary Fig-
ure S14). Thus, the pSer5 CTD can bind to the same sites in
both orientations, although the CTD with the ‘mammalian’
orientation has a higher relative binding affinity than the
CTD bound in the ‘yeast’ orientation (Systems 6 and 11;
Figure 8C).
We suggest that such bidirectional CTD binding to the
same interaction sites is enabled because the CTD hep-
tad motif is almost completely palindromic (Figure 8D),
and therefore the positions of the CTD residues remain
the same in both directions. To our knowledge this fea-
ture of the CTD sequence and structure has not been pre-
viously discussed. To see this, the canonical heptad mo-
tif must be viewed starting with Ser5 and placing Tyr1 at
the centre. The GTase–CTD interaction mostly involves the
CTD sidechains, such as the pSer and Tyr1 interactions, but
not the backbone, and therefore the chirality of the pep-
tide backbone is unlikely to affect the GTase–CTD bind-
ing affinity. This also agrees with our finding that the CDS
pockets can be occupied in different heptad orders (Fig-
ure 3B). As a result, the C. albicans CTD conformation
can be superimposed onto the human GTase with few mi-
nor steric clashes, and this conformation remains stable for
the duration of the simulation, despite the fact that it is in
the ‘opposite orientation’. Bidirectionality of peptide bind-
ing has been observed for other protein-peptide interac-
tions, including the WW domain, MHC class II, SH3 do-
main and O-GlcNAcase (84–87). In particular, the WW do-
main in Pin1 binds to CTD phosphopeptides in an oppo-
site direction to other examples of WW domain protein–
peptide interactions (84). Bidirectional peptide binding has
been suggested to have implications for binding specificity,
as changes to the peptide sequence or phosphorylation pat-
tern are likely to introduce steric constraints that may pre-
vent binding in a particular orientation (85).
We hypothesize that the palindromic nature of the CTD
contributes to its function in binding to such a wide vari-
ety of partners during transcription. It may allow the CTD
to have specific interactions, such as interactions with the
specific CTD kinases, while also being able to recruit fac-
tors such as the CE, where the CTD can bind in a variety
of conformations. The palindromic nature of the CTD also
has implications for how the code could be read, with the
pSer5 and pSer2 being in distinct locations along the palin-
drome. This could, in part, explain why a major transition in
phosphorylation occurs between Ser5 and Ser2 rather than
Ser2 and Ser7, which are in the same relative position within
the palindrome (20,22,25,88).
CONCLUSION
Recruitment of the CE by the carboxyl-terminal domain of
RNA Polymerase II (CTD) is an essential stage of mRNA
capping, localizing the CE to the site of transcription and
stimulating the activity of its guanylyltransferase (GTase)
domain (15–17). Despite a number of studies of the GTase–
CTD interface, fundamental questions remain about the
molecular details of this interaction (12,27,30–33,76,83).
We have carried out an extensive (a cumulative length of 22
s) and systematic (a total of 17 simulation systems) study
of the GTase–CTD interaction using molecular dynamics
(MD) simulations, in which we varied the phosphorylation
code, length and orientation of the bound CTD fragment.
We have subsequently confirmed the main computational
predictions by performing a series of biochemical assays.
Through this approach, we have identified several dis-
tinct characteristics of the GTase–CTD interaction. Most
notably, we have identified two novel interaction sites on
the human CE GTase surface (CDS2 and CDS–Y2). In ad-
dition to this we have shown that the disordered flanks of
the GTase contribute significantly to CTD binding. Struc-
tural and sequence analysis between animals and yeasts re-
veals that the novel GTase–CTD interaction sites are highly
conserved, leading us to conclude that the GTase–CTD in-
teraction sites have undergone considerably higher selection
pressure than previously considered. The binding free en-
ergy analysis and binding assays have demonstrated that the
phosphoserine interactions are the main contributors to the
GTase–CTD interaction.
Our results confirm that the novel CDS2 site is essential
for GTase activation, revealing a previously missing link for
understanding the molecular mechanism of GTase activa-
tion by the CTD. Through the simulation of the K294A
GTase mutant, we provide the first structural insights into
how the GTase active site and CTD binding sites are con-
nected through an allosteric pathway, and put forward the
proposal for the allosteric mechanism, in which R358 and
R411 of CDS2 and E436 near the magnesium binding site
play an important role. E436 and R411 are highly conserved
in animals but absent in yeasts, which could explain why the
allosteric activation has been observed for the mammalian
GTase but not yeast (31).
This work has also characterized how the GTase–CTD
interaction depends on the CTD phosphorylation code.
Our simulations and biochemical assays both show that
these interactions are not pSer5 CTD specific and are also
essential for pSer2 CTD binding. We conclude that the oc-
cupation of the pSer interaction sites does not confer al-
losteric activation alone, instead the distinct conformations
that the pSer5 CTD peptides adopt when bound at these
sites determine whether the GTase becomes activated. Over-
all, this work moves forward our current understanding of
the GTase–CTD interaction, from one of static interaction
sites obtained from crystal structures to a more complex
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picture of transient interactions and structural ensembles,
where the CDS sites are occupied in different orders and
directions.
Finally, this work sheds light on the structural features
of the CTD. Our simulations clearly demonstrate the CTD
looping out mechanism first described by Fabrega et al.
(31), in a variety of simulation systems with different CTD
initial conformations, orientations and phosphorylation
patterns. Moreover, we show that the order of heptad bind-
ing to the CDS sites can change more drastically, leading
to the identification of the GTase–CTD interaction bidirec-
tionality. We conclude that this bidirectionality is the result
of the CTD motif being palindromic. The palindromic na-
ture of the CTD has not been explored previously but it is
likely to have implications for how the CTD is written and
read, affecting a number of stages of gene regulation.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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Tufféry,P. (2016) PEP-FOLD3: faster de novo structure prediction for
linear peptides in solution and in complex. Nucleic Acids Res., 44,
W449–W454.
52. Case,D.A., Betz,R.M., Cerutti,D.S., Cheatham,T.E., Darden,T.A.,
Duke,R.E., Giese,T.J., Gohlke,H., Goetz,A.W., Homeyer,N. et al.
(2016) AMBER16.
53. Maier,J.A., Martinez,C., Kasavajhala,K., Wickstrom,L.,
Hauser,K.E. and Simmerling,C. (2015) ff14SB: improving the
accuracy of protein side chain and backbone parameters from
ff99SB. J. Chem. Theory Comput., 11, 3696–3713.
54. Homeyer,N., Horn,A. H.C., Lanig,H. and Sticht,H. (2006) AMBER
force-field parameters for phosphorylated amino acids in different
protonation states: phosphoserine, phosphothreonine,
phosphotyrosine, and phosphohistidine. J. Mol. Model., 12, 281–289.
55. Word,J.M., Lovell,S.C., Richardson,J.S. and Richardson,D.C. (1999)
Asparagine and glutamine: using hydrogen atom contacts in the
choice of side-chain amide orientation. J. Mol. Biol., 285, 1735–1747.
56. Hopkins,C.W., Le Grand,S., Walker,R.C. and Roitberg,A.E. (2015)
Long-time-step molecular dynamics through hydrogen mass
repartitioning. J. Chem. Theory Comput., 11, 1864–1874.
57. Berendsen,H.J.C., Postma,J.P.M., van Gunsteren,W.F., DiNola,A.
and Haak,J.R. (1984) Molecular dynamics with coupling to an
external bath. J. Chem. Phys., 81, 3684–3690.
58. Miyamoto,S. and Kollman,P.A. (1992) Settle: an analytical version of
the SHAKE and RATTLE algorithm for rigid water models. J.
Comput. Chem., 13, 952–962.
59. Hamelberg,D., de Oliveira,C.A.F. and McCammon,J.A. (2007)
Sampling of slow diffusive conformational transitions with
accelerated molecular dynamics. J. Chem. Phys., 127, 155102.
60. de Oliveira,C.A.F., Hamelberg,D. and McCammon,J.A. (2008)
Coupling accelerated molecular dynamics methods with
thermodynamic integration simulations. J. Chem. Theory Comput., 4,
1516–1525.
61. Humphrey,W., Dalke,A. and Schulten,K. (1996) VMD: visual
molecular dynamics. J. Mol. Graph., 14, 33–38.
62. Baker,N.A., Sept,D., Joseph,S., Holst,M.J. and McCammon,J.A.
(2001) Electrostatics of nanosystems: application to microtubules and
the ribosome. Proc. Natl. Acad. Sci. U.S.A., 98, 10037–10041.
63. Suhre,K. and Sanejouand,Y.-H. (2004) ElNemo: a normal mode web
server for protein movement analysis and the generation of templates
for molecular replacement. Nucleic Acids Res., 32, W610–W614.
64. Waterhouse,A.M., Procter,J.B., Martin,D.M.A., Clamp,M. and
Barton,G.J. (2009) Jalview version 2-a multiple sequence alignment
editor and analysis workbench. Bioinformatics, 25, 1189–1191.
65. Sievers,F., Wilm,A., Dineen,D., Gibson,T.J., Karplus,K., Li,W.,
Lopez,R., McWilliam,H., Remmert,M., Söding,J. et al. (2011) Fast,
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